In situ hybridization for high-risk HPV E6/E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer

Autor: Timo Carpén, Antti Mäkitie, Caj Haglund, Suvi Silén, Jaana Hagström, Reija Randén-Brady, Satu Maria Remes, Lauri Jouhi, Petri S. Mattila, Jussi Tarkkanen, Stina Syrjänen
Přispěvatelé: HUSLAB, Department of Pathology, University of Helsinki, Korva-, nenä- ja kurkkutautien klinikka, HUS Head and Neck Center, Clinicum, Department of Ophthalmology and Otorhinolaryngology, HUS Abdominal Center, Department of Surgery, II kirurgian klinikka, University Management, Translational Cancer Biology (TCB) Research Programme, Research Programs Unit, Helsinki University Hospital Area, Research Program in Systems Oncology, Faculty of Medicine, Medicum
Rok vydání: 2019
Předmět:
0301 basic medicine
Male
Oropharynx
law.invention
chemistry.chemical_compound
0302 clinical medicine
NECK-CANCER
law
P16 IMMUNOHISTOCHEMISTRY
Medicine
Papillomaviridae
Polymerase chain reaction
In Situ Hybridization
P16 immunohistochemistry
virus diseases
female genital diseases and pregnancy complications
3. Good health
Oropharyngeal Neoplasms
PCR
030220 oncology & carcinogenesis
Carcinoma
Squamous Cell
Immunohistochemistry
RNA
Viral
Female
SQUAMOUS-CELL CARCINOMA
CRITICAL-ISSUES
In situ hybridization
TREATMENT DE-ESCALATION
DIAGNOSIS
Sensitivity and Specificity
VALIDATION
Pathology and Forensic Medicine
03 medical and health sciences
Carcinoma
Humans
HEAD
Messenger RNA
business.industry
Papillomavirus Infections
Cancer
DNA
Oncogene Proteins
Viral
medicine.disease
HUMAN-PAPILLOMAVIRUS DETECTION
030104 developmental biology
chemistry
Viral infection
Cancer research
RNA
3111 Biomedicine
business
Zdroj: Human pathology. 90
ISSN: 1532-8392
2000-2009
Popis: Current human papillomavirus (HPV) detection methods in oropharyngeal squamous cell carcinoma (OPSCC) have varying sensitivity and specificity. We aimed to compare different HPV-detection methods against the test used in clinical practice, ie, p16 immunohistochemistry (IHC) and to evaluate whether another HPV-detection test additional to p16 IHC would be worthwhile in OPSCC specimens. The study cohort comprised 357 consecutive OPSCC patients during two time periods: 2000-2009 and 2012-2016. From tumor tissue slides, HPV mRNA via in situ hybridization (ISH), HPV DNA via ISH and HPV DNA via polymerase chain reaction (PCR) were detected. The results of these methods were compared with p16 IHC results. Additionally, clinicopathological factors were compared with the methods studied. The sensitivity of HPV mRNA ISH, HPV DNA ISH and HPV DNA PCR were 93.4%, 86.3%, and 83.5%, respectively. The corresponding specificity was 92.4%, 95.3%, and 89.1%, respectively. The negative predictive value for p16 IHC was highest (89.0%) when using mRNA ISH, and followed by DNA ISH (83.5%). ISH for high-risk HPV E6/E7 mRNA was found to be a highly specific and sensitive method for detecting HPV in OPSCC. As p16 protein may be overexpressed due to HPV-independent mechanisms, all p16 IHC positive OPSCCs should be considered for retesting using mRNA ISH in order to verify transcriptionally active HPV. This is especially critical when considering de-escalated treatment approaches for patients with HPV-positive tumors and still maintaining favorable outcomes for this subgroup of patients. (C) 2019 Elsevier Inc. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: